(Q38241232)

31 August 2017

title

IL-6 biology: implications for clinical targeting in rheumatic disease (English)

1 reference

31 August 2017

Stefan Rose-John

2

0 references

author name string

Leonard H Calabrese

series ordinal

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

19 August 2014

1 reference

Nature Reviews Rheumatology

31 August 2017

published in

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

12

1 reference

31 August 2017

page(s)

720-727

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.127

31 August 2017

exact match

0 references

cites work

The paradigm of IL-6: from basic science to medicine

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6: historical background, genetics and biological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6 as a therapeutic target in candidate inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

ADAM17: a molecular switch to control inflammation and tissue regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Structure of an extracellular gp130 cytokine receptor signaling complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The regenerative activity of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Inflammatory bone loss: pathogenesis and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The value of blocking IL-6 outside of rheumatoid arthritis: current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6 and its receptor: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6: from basic science to medicine--40 years in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The soluble interleukin-6 receptor is generated by shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Soluble receptors for cytokines and growth factors: generation and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Human interleukin-6 facilitates hepatitis B virus infection in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Hyper-IL-6 gene therapy reverses fulminant hepatic failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Sympathetic neurons can produce and respond to interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Trp53 deficiency protects against acute intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Hitting a complex target: an update on interleukin-6 trans-signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6 and the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Heterogeneity of human effector CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

JAK and STAT signaling molecules in immunoregulation and immune-mediated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Therapeutic targeting of the interleukin-6 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Immune mechanisms in medium and large-vessel vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Integrated safety in tocilizumab clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Is Interleukin-6 Receptor Blockade the Holy Grail for Inflammatory Diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Studies on the structure and regulation of the human hepatic interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

A bioactive designer cytokine for human hematopoietic progenitor cell expansion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute Inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

An essential role for ectodomain shedding in mammalian development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

The interleukin 6 pathway and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Cutting Edge: Trans-Signaling via the Soluble IL-6R Abrogates the Induction of FoxP3 in Naive CD4+CD25- T Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Tocilizumab: a novel therapy for patients with large-vessel vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.127

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

31 March 2020

1 reference

12 December 2020

IL-6 signaling promotes tumor growth in colorectal cancer

1 reference

12 December 2020

Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.

1 reference

12 December 2020

Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor

1 reference

12 December 2020

Lethal tuberculosis in interleukin-6-deficient mutant mice

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2014.127

1 reference

Dimensions Publication ID

31 August 2017

1013053699

0 references

1 reference